Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

The Northern BC Myeloma Support Group has been recognized by its parent national organization for going the extra mile in its ...

Multiple myeloma is a type of cancer where plasma cells in bone marrow replicate out of control. Doctors use the acronym CRAB to diagnose myeloma by identifying four symptoms. The National Cancer ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

At six months, the median PFS rates were 89.5% and 87.6% in the ... for the treatment of KRd56 and KRd27 in patients with relapsed or refractory multiple myeloma. However, it’s important to note that ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...